Event-free survival extended with long-term finerenone in heart failure

Long-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according to a brief report published online Sept. 27 in JAMA Cardiology to coincide with the annual meeting of the Heart Failure Society of America, held virtually from Sept. 27 to 30.

Muthiah Vaduganathan, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues estimated the long-term treatment effects of finerenone if treated during a patient’s lifetime in patients with heart failure with mildly reduced or preserved ejection fraction.

Analyses included data from the FINEARTS-HF trial, which was conducted in 37 countries across 653 sites. Participants, who were aged 40 years and older and had symptomatic heart failure and left ventricular ejection fraction of 40% or higher, were randomly assigned to finerenone (titrated to 20 or 40 mg) or placebo; 6,001 participants were included in the analysis.

The researchers found that for a 55-year-old participant, mean survival free from the primary composite outcome of time to cardiovascular death or worsening heart failure event was 13.6 and 10.5 years with finerenone and placebo, respectively, representing a gain of 3.1 years in event-free survival. For a 65-year-old participant, mean event-free survival was 11.0 and 8.9 years with finerenone and placebo, respectively, representing a gain of 2.0 years.

For every starting age between 50 and 80 years, the projected mean event-free survival was numerically greater with finerenone versus placebo. Even among individuals already treated with a sodium-glucose cotransporter 2 inhibitor, there were lifetime gains in event-free survival observed (3.1 years for a 65-year-old participant).

“The relative benefits reported during follow-up in the FINEARTS-HF trial can be interpreted together with these new projections of the expected absolute benefits with lifetime use of finerenone,” the authors write.

More information:
Muthiah Vaduganathan et al, Estimated Long-Term Benefits of Finerenone in Heart Failure, JAMA Cardiology (2024). DOI: 10.1001/jamacardio.2024.3782

Copyright © 2024 HealthDay. All rights reserved.

Citation:
Event-free survival extended with long-term finerenone in heart failure (2024, September 30)
retrieved 6 October 2024
from https://medicalxpress.com/news/2024-09-event-free-survival-term-finerenone.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

Earth orbits the ...

Explore More

30-year risk of cardiovascular disease may help inform blood pressure treatment decisions

A comparison of two risk prediction tools used to calculate an individual’s risk of developing cardiovascular disease (CVD) suggests that the long-term, 30-year risk should be considered in addition to

Aspirin as effective as blood thinner injections to prevent deadly complications in patients hospitalized with bone fractures

Patients hospitalized with fractures typically receive an injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots. A new clinical trial, however, found that inexpensive over-the-counter aspirin is just as

No advantage for ‘no-touch’ vein harvesting over conventional technique for coronary bypass, research finds

Credit: Pixabay/CC0 Public Domain No-touch graft harvesting did not appear to be beneficial compared with the conventional technique for coronary artery bypass grafting (CABG), according to late-breaking research presented in